Overview

A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

Status:
Withdrawn

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

This is a phase II, multicenter, single-arm study to assess the safety and feasibility of combining crenolanib with fludarabine and cytarabine chemotherapy in pediatric patients with relapsed/refractory FLT3-mutated AML. Patients will receive up to two courses of salvage chemotherapy with fludarabine, cytarabine, and crenolanib. Response will be assessed between day 29-43 of each course.

Phase:

Phase 2

Details

Lead Sponsor:

Arog Pharmaceuticals, Inc.

Treatments:

Crenolanib
Cytarabine
Fludarabine
Fludarabine phosphate
Vidarabine